Asundexian Versus Apixaban in Patients With Atrial Fibrillation

Area of Science:

• Pharmacology and Medicine
• Cardiovascular Research
• Hematology

Background:

• Traditional anticoagulants like warfarin and direct oral anticoagulants (DOACs) carry risks of bleeding complications.
• Factor XIa inhibition is a novel strategy to reduce thrombotic risk while preserving hemostasis.
• Asundexian is a selective Factor XIa inhibitor representing a potential advancement in anticoagulation therapy.

Purpose of the Study:

• To review preclinical and clinical evidence on Asundexian.
• To evaluate its pharmacological mechanism, efficacy, safety, and potential clinical applications.
• To assess its role in contemporary anticoagulation therapy based on data from PACIFIC-AF and PACIFIC-STROKE trials.

Main Methods:

• Narrative review of available preclinical and clinical data on Asundexian.
• Focused review of key data from major clinical trials, including PACIFIC-AF and PACIFIC-STROKE.
• Evaluation of Asundexian's efficacy, safety, and convenience compared to conventional anticoagulants.

Main Results:

• Asundexian effectively reduces stroke and systemic embolism incidence in atrial fibrillation and high-risk ischemic stroke patients.
• It demonstrates a lower risk of major bleeding compared to conventional anticoagulants.
• Fixed dosing, oral administration, and no routine monitoring enhance convenience and adherence.

Conclusions:

• Asundexian offers a potentially safer anticoagulation method by targeting Factor XIa, balancing efficacy and safety.
• Early clinical results are encouraging, but large-scale, long-term studies are needed for diverse populations.
• Asundexian may redefine anticoagulation standards and improve patient outcomes.